ProCE Banner Activity

Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM

Slideset Download
Conference Coverage

The first clinical results of iberdomide in combination with either daratumumab/dex or bortezomib/dex is well tolerated with encouraging efficacy in heavily pretreated patients with myeloma.

Released: December 15, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology